Sullivan Timothy Eugene
Insider CIK 1707000 · APLS Chief Financial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 34,533 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 23,958 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 84,946 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 232,903 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 82,500 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 43,183 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 45,000 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 70,125 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 60,242 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 58,140 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | U Tender | 2026-05-14 | 2026-05-14 | 71,492 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | U Tender | 2026-05-14 | 2026-05-14 | 140,945 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 58,140 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 34,447 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 11,874 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 6,872 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 41,250 | — | $0 | 41,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 58,140 | — | $0 | 58,140 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 29,070 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 29,070 | — | $0 | 29,070 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 30,620 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 30,620 | — | $0 | 30,620 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 41,250 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | G Gift | 2026-04-17 | 2026-04-20 | 11,096 | — | $0 | 71,492 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | G Gift | 2026-04-17 | 2026-04-20 | 11,096 | — | $0 | 140,945 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-01-28 | 2026-01-30 | 58,140 | — | $0 | 152,041 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-22 | 2026-01-23 | 10,287 | $21.77 | $223.9K | 93,901 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-20 | 2026-01-21 | 2,892 | $19.79 | $57.2K | 104,188 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-13 | 2026-01-15 | 3,856 | $22.19 | $85.6K | 107,080 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2025-10-21 | 2025-10-23 | 10,000 | — | $0 | 232,903 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-10-21 | 2025-10-23 | 10,000 | $28.03 | $280.3K | 110,936 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2025-10-21 | 2025-10-23 | 10,000 | $10.03 | $100.3K | 120,936 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2025-09-08 | 2025-09-10 | 15,000 | — | $0 | 242,903 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-09-08 | 2025-09-10 | 10,000 | $27.83 | $278.3K | 60,396 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2025-09-08 | 2025-09-10 | 15,000 | $10.03 | $150.4K | 143,665 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-09-08 | 2025-09-10 | 32,729 | $27.86 | $911.8K | 110,936 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2025-06-09 | 2025-06-11 | 82,500 | $19.39 | $1.60M | 82,500 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-29 | 2025-01-30 | 546 | $29.52 | $16.1K | 128,665 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-22 | 2025-01-23 | 3,088 | $30.43 | $94.0K | 129,211 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2025-01-21 | 2025-01-21 | 45,929 | — | $0 | 132,299 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-17 | 2025-01-21 | 1,730 | $29.96 | $51.8K | 86,370 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-13 | 2025-01-14 | 2,170 | $28.70 | $62.3K | 88,100 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2024-12-31 | 2025-01-03 | 10,054 | — | $0 | 84,946 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2024-12-31 | 2025-01-03 | 1,042 | — | $0 | 23,958 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2024-12-31 | 2025-01-03 | 1,042 | $14.95 | $15.6K | 80,216 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2024-12-31 | 2025-01-03 | 10,054 | $13.85 | $139.2K | 90,270 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | G Gift | 2024-04-18 | 2024-04-19 | 14,164 | — | $0 | 70,396 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | G Gift | 2024-04-18 | 2024-04-19 | 14,164 | — | $0 | 79,174 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2024-04-01 | 2024-04-02 | 4,000 | — | $0 | 257,903 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-04-01 | 2024-04-02 | 4,000 | $58.66 | $234.6K | 93,338 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2024-04-01 | 2024-04-02 | 4,000 | $10.03 | $40.1K | 97,338 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2024-03-01 | 2024-03-05 | 6,000 | — | $0 | 261,903 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2024-03-01 | 2024-03-05 | 6,000 | $10.03 | $60.2K | 99,338 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-03-01 | 2024-03-05 | 4,000 | $62.86 | $251.4K | 95,338 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-03-01 | 2024-03-05 | 2,000 | $63.95 | $127.9K | 93,338 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-02-12 | 2024-02-13 | 1,431 | $67.77 | $97.0K | 93,338 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-29 | 2024-01-31 | 906 | $64.14 | $58.1K | 94,769 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-22 | 2024-01-23 | 3,551 | $65.00 | $230.8K | 95,675 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2024-01-16 | 2024-01-17 | 34,533 | $66.30 | $2.29M | 34,533 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-16 | 2024-01-17 | 2,235 | $66.81 | $149.3K | 99,226 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2024-01-16 | 2024-01-17 | 23,748 | — | $0 | 101,461 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2023-11-30 | 2023-12-01 | 14,158 | — | $0 | 267,903 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-11-30 | 2023-12-01 | 300 | $54.79 | $16.4K | 77,713 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2023-11-30 | 2023-12-01 | 14,158 | $10.03 | $142.0K | 91,871 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-11-30 | 2023-12-01 | 13,858 | $54.73 | $758.4K | 78,013 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2023-07-03 | 2023-07-06 | 6,779 | — | $0 | 282,061 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-07-03 | 2023-07-06 | 3,287 | $90.42 | $297.2K | 78,013 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2023-07-03 | 2023-07-06 | 6,779 | $10.03 | $68.0K | 84,492 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-07-03 | 2023-07-06 | 300 | $91.10 | $27.3K | 77,713 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-07-03 | 2023-07-06 | 3,192 | $89.41 | $285.4K | 81,300 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2023-06-05 | 2023-06-06 | 69,779 | — | $0 | 288,840 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2023-06-05 | 2023-06-06 | 69,779 | $10.03 | $699.9K | 147,492 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-06-05 | 2023-06-06 | 1,600 | $90.60 | $145.0K | 145,892 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-06-05 | 2023-06-06 | 30,609 | $87.79 | $2.69M | 115,283 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-06-05 | 2023-06-06 | 30,506 | $89.83 | $2.74M | 77,713 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-06-05 | 2023-06-06 | 7,064 | $88.36 | $624.2K | 108,219 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | G Gift | 2023-05-03 | 2023-05-03 | 20,000 | — | $0 | 56,232 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | G Gift | 2023-05-03 | 2023-05-03 | 20,000 | — | $0 | 77,713 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | G Gift | 2023-04-19 | 2023-04-20 | 36,232 | — | $0 | 97,713 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | G Gift | 2023-04-19 | 2023-04-20 | 36,232 | — | $0 | 36,232 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-02-21 | 2023-02-22 | 16,572 | — | $0 | 16,572 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-02-21 | 2023-02-22 | 11,683 | — | $0 | 134,919 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-02-21 | 2023-02-22 | 974 | $58.50 | $57.0K | 133,945 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-02-10 | 2023-02-14 | 975 | $51.21 | $49.9K | 123,236 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-01-27 | 2023-01-30 | 551 | $52.77 | $29.1K | 124,211 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-01-20 | 2023-01-24 | 2,379 | $52.05 | $123.8K | 124,762 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-01-12 | 2023-01-17 | 43,183 | $52.66 | $2.27M | 43,183 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-01-12 | 2023-01-17 | 27,488 | — | $0 | 127,141 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other deriv | 2022-04-25 | 2023-01-17 | 22,500 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2022-04-25 | 2023-01-17 | 3,750 | — | $0 | 99,653 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2022-02-10 | 2022-02-14 | 875 | $47.12 | $41.2K | 103,403 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2022-01-28 | 2022-02-01 | 650 | $38.59 | $25.1K | 104,278 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2022-01-21 | 2022-01-25 | 43,670 | — | $0 | 43,670 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2022-01-21 | 2022-01-25 | 30,787 | — | $0 | 104,928 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2021-06-08 | 2021-06-09 | 39,880 | — | $0 | 358,619 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2021-06-08 | 2021-06-09 | 39,880 | $10.03 | $400.0K | 74,141 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2021-02-10 | 2021-02-11 | 858 | $47.72 | $40.9K | 34,261 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2021-01-28 | 2021-02-01 | 45,000 | — | $0 | 45,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2021-01-28 | 2021-02-01 | 22,500 | — | $0 | 22,500 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2021-01-28 | 2021-02-01 | 3,750 | — | $0 | 35,119 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2021-01-28 | 2021-02-01 | 7,500 | — | $0 | 31,369 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2020-02-10 | 2020-02-12 | 70,125 | — | $0 | 70,125 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2020-02-10 | 2020-02-12 | 11,688 | — | $0 | 23,387 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | P Buy | 2019-08-29 | 2019-09-03 | 11,699 | $29.71 | $347.6K | 11,699 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2019-02-08 | 2019-02-12 | 95,000 | — | $0 | 95,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2018-02-16 | 2018-02-21 | 25,000 | — | $0 | 25,000 | SEC↗ |